A Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Effectiveness of QLS4131 for Injection in Patients With Systemic Lupus Erythematosus
Latest Information Update: 10 Jun 2025
At a glance
- Drugs QLS-4131 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 10 Jun 2025 New trial record